From CLL to Multiple Myeloma - Spleen Tyrosine Kinase (SYK) influences multiple myeloma cell survival and migration

Br J Haematol. 2016 Sep;174(6):985-9. doi: 10.1111/bjh.13825. Epub 2015 Oct 22.
No abstract available

Keywords: R406; chronic lymphocytic leukemia; multiple myeloma; spleen tyrosine kinase; therapy.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Cell Line, Tumor
  • Cell Movement / drug effects
  • Cell Survival / drug effects
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Leukemia, Lymphocytic, Chronic, B-Cell / pathology
  • Middle Aged
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / pathology
  • Oxazines / pharmacology
  • Oxazines / therapeutic use
  • Protein Kinase Inhibitors / therapeutic use
  • Pyridines / pharmacology
  • Pyridines / therapeutic use
  • Syk Kinase / analysis
  • Syk Kinase / antagonists & inhibitors*
  • Syk Kinase / pharmacology

Substances

  • N4-(2,2-dimethyl-3-oxo-4H-pyrid(1,4)oxazin-6-yl)-5-fluoro-N2-(3,4,5-trimethoxyphenyl)-2,4-pyrimidinediamine
  • Oxazines
  • Protein Kinase Inhibitors
  • Pyridines
  • SYK protein, human
  • Syk Kinase